You just read:

Sangamo Announces European Medicines Agency Recommendation Of Orphan Medicinal Product Designation For Investigational Genome Editing Treatments For MPS I And MPS II

News provided by

Sangamo Therapeutics, Inc.

Dec 07, 2017, 15:22 EST